Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: Convictions versus confidence inhibits sustainability and never forget sentiment is a subtraction

June 19, 2019 5:16pm

Volume and percentage (%) of the upside and downside are still weak

A raging battle of my 45 covered companies as they dive and jive while the healthcare sector rose 1%

Pre-open indications: 7 HIT and 0 MISS

Remember after pain, there’s usually gain

The remainder of the month’s trading sessions will be critical for the RegMed sector which will establish whether expectation of the month and quarter’s (Q2) initiate a slow downdraft.

Markets and indexes:

The Dow closed up +76.95 points or +0.29% to 26,542.49
The S&P closed up +8.71 points or +0.30% at 2,926.46
The NASDAQ was up +33.44 points or +0.42% to 7,987.32

Henry’omics:

The sector was purged after Tuesday’s surge …

The S&P 500 approached a record high on Wednesday after the Fed signaled potential interest cuts later this year, reassuring investors worried that the U.S. - China trade war could stall economic growth.

The sector on a macro scale was up; health care stocks, which typically perform well after the Fed cuts rates, were …performers on Wednesday yet specific “pockets” felt some pain.

My companies within the sector best gains were led by Global Blood Therapeutics (GBT), bluebird bio (BLUE) and Spark therapeutics (ONCE) while the “downers” were led by ReNeuron (RENE.L), CRISPR Therapeutics (CRSP) and Regenxbio (RGNX).

A couple of secondary stand-outs were Vericel (VCEL +$0.63) and Ultragenyx (RARE +$0.97) while Cesca Therapeutics (KOOL -$0.22) post reverse got hammered and Alnylam Pharmaceuticals (-$1.05) felt the pinch along with Applied Genetic Technologies (AGTC -$0.16) keeps getting slammed by day trading!

Wednesday’s advance/decline line scenario of 45 covered companies:

The open was negative with an A/DL of 14/26 with 3 flats and 2 acquired;
The mid-day was barely positive with an A/DL of 22/21 with 0 flat and 2 acquired;
The close was negative with an A/DL of 15/26 and 2 flats and 2 acquired;

Pre-open post: “weak volume is driving the upside. Two (2) weeks before the month and Q2 ends, re-balance risk, set appropriate “earnings” anticipation to ensure a portfolio is comfortably aligned with expectation.”

Pre-open indications: 7 HIT and 0 MISS

bluebird bio (BLUE) closed up +$1.36 – hit;
Intrexon (XON) closed down -$0.05 – hit;
Regenxbio (RGNX) closed down -$1.06 – hit;
ReNeuron (RENE.L) closed down -$17.50 – hit;
uniQure N.V. (QURE) closed down -$0.57 – hit;
Sage Therapeutics (SAGE) closed down -$0.56 – hit;
Voyager Therapeutics (VYGR) closed down -$0.01 – hit;

Worst-performers (bottom 5) were:

Wednesday: RENE.L (-$17.50), CRSP (-$1.25), RGNX (-$1.08), ALNY (-$1.05) and FIXX (-$0.97);
Tuesday: RENE.L (-$5.00), BLUE (-$4.38), QURE (-$3.13), AXGN (-$1.46) and MDXG (-$0.08);
Monday: RENE.L (-$7.50), CLBS (-$0.29), KOOL (-$0.16), MESO (-$0.137) and HSGX (-$0.059); ` `

Posting gains (top 5) were:

Wednesday: GBT (+$2.25), BLUE (+$1.36), ONCE (+$1.27), RARE (+$0.97) and VCEL (+$0.63);
Tuesday: SAGE (+$2.61), ONCE (+$2.26), GBT (+$2.06), RGNX (+$1.60) and ALNY (+$1.52);
Monday: QURE (+$8.59), SAGE (+$5.52), BLUE (+$5.04), CRSP (+$3.80) and RARE (+$3.74);

Upside volume stats:

Wednesday: 4 out of the 15 upside had higher than the 3 month average volume;
Tuesday: 9 out of the 33 upside had higher than the 3 month average volume;
Monday: 10 out of the 33 upside had higher than the 3 month average volume;

Downside volume stats:

Wednesday: 4 out of the 26 downside had higher than the 3 month average volume;
Tuesday: 3 out of the 9 downside had higher than the 3 month average volume;
Monday: 3 out of the 10 downside had higher than the 3 month average volume;

The week’s percentage (%) indicators:

Wednesday’s range of the 15 upside was +0.13% (BOLD) to +4.40% (VSTM) while the 26 downside ranged from -0.04% (VYGR) to -7.37% (RENE.L);
Tuesday’s range of the 33 upside was +0.05% (PSTI) to +13.16% (XON) while the 9 downside ranged from -1.41% (MESO) to -12.25% (HSGX -$0.029);
Monday’s range of the 33 upside was +0.04% (PSTI) to +25% (VSTM +$0.35) while the 10 downside ranged from -0.11% (BLFS) to -20% (HSGX -0.059);

2 flat – CLBS and BLCM with 2 acquired (AST & OSIR) and the Spark Therapeutics’ (ONCE) acquisition by Roche still being delayed

The iShares NASDAQ Biotechnology (IBB) indicator:

Wednesday closed up +0.57%
Tuesday closed up +1.38%
Monday closed up +2.96%
Friday closed down -0.93%
Thursday closed up +0.75%
Last Wednesday closed up +0.61%

June’s sessions:

Wednesday closed NEGATIVE with 26 decliners, 15 advancers, 2 flat and 2 acquired (AST & OSIR);

Tuesday closed POSITIVE with 33 decliners, 9 advancers, 1 flat and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 10 decliners, 32 advancers, 1 flat and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 30 decliners, 11 advancers, 2 flat and 2 acquired (AST & OSIR);

Thursday closed POSITIVE with 10 decliners, 32 advancers, 1 flat and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 17 decliners, 26 advancers, 0 flats and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 32 decliners, 7 advancers, 4 flats and 2 acquired (AST & OSIR);

Monday closed NEUTRAL with 21 decliners, 21 advancers, 1 flat and 2 acquired (AST & OSIR);

Friday closed POSITIVE with 10 decliners, 31 advancers, 2 flats and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 37 decliners, 5 advancers, 1 flat and 2 acquired (AST & OSIR);

Wednesday closed NEGATIVE with 24 decliners, 17 advancers, 2 flat and 2 acquired (AST & OSIR);

Tuesday closed POSITIVE with 10 decliners, 32 advancers, 1 flat and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 17 decliners, 25 advancers, 1 flat and 2 acquired (AST & OSIR);

Q2/19 so far:

In May, there were 14 negative, 1 holiday and 8 positive closes;
In April, there has been 10 positive and 11 negative closes;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.